Biomimetic nanotherapeutics for targeted drug delivery to glioblastoma multiforme.
Xin Yuan LimSharah Mae CapinpinNagarjun BolemAaron Song Chuan FooWai-Cheong George YipAlan Prem KumarDaniel Boon Loong TehPublished in: Bioengineering & translational medicine (2023)
Glioblastoma multiforme (GBM) is an aggressive brain tumor with poor prognosis and high mortality, with no curative treatment to date as limited trafficking across the blood-brain barrier (BBB) combined with tumor heterogeneity often leads to therapeutic failure. Although modern medicine poses a wide range of drugs that are otherwise efficacious in treating other tumors, they often do not achieve therapeutic concentrations in the brain, hence driving the need for more effective drug delivery strategies. Nanotechnology, an interdisciplinary field, has been gaining immense popularity in recent years for remarkable advancements such as nanoparticle (NP) drug carriers, which possess extraordinary versatility in modifying surface coatings to home in on target cells, including those beyond the BBB. In this review, we will be highlighting recent developments in biomimetic NPs in GBM therapy and how these allowed us to overcome the physiological and anatomical challenges that have long plagued GBM treatment.
Keyphrases
- poor prognosis
- drug delivery
- cancer therapy
- long non coding rna
- type diabetes
- induced apoptosis
- emergency department
- cardiovascular events
- healthcare
- stem cells
- cell cycle arrest
- drug induced
- rectal cancer
- cardiovascular disease
- oxidative stress
- mesenchymal stem cells
- multiple sclerosis
- electronic health record
- drug release
- signaling pathway
- subarachnoid hemorrhage